Limited access to on-demand treatment in hereditary angioedema is linked to delayed treatment and impaired patient-reported outcomes: A multinational real-world study.

Cathryn F McDougall, Hugo W F Mak, Jane C Y Wong, Philip H Li, Ricardo D Zwiener, Jonny G Peter

Abstract read

In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cathryn F McDougallAllergy and Immunology Unit, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa.

Hugo W F MakDivision of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.

Jane C Y WongDivision of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.

Philip H LiDivision of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.

Ricardo D ZwienerAllergy and Immunology Department. Hospital Universitario Austral, Pilar, Buenos Aires, Argentina.

Jonny G PeterAllergy and Immunology Unit, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary angioedema (HAE) is a rare inherited disorder characterized by recurrent episodes of soft tissue swelling. Disparities in HAE care have been described in Asia, Africa, and South America. Less is known about how patients in these regions experience and respond to these limitations. Objectives: Our aim was to evaluate access to on-demand treatment (ODT), reasons for treatment delays, and the impact of disease control and health-related quality of life (HRQoL) among patients with HAE in Hong Kong, Argentina, and South Africa. Method: A cross-sectional survey adapted from a previously published Western cohort, was conducted. Disease control and HRQoL were assessed by using the Angioedema Control Test and the Angioedema Quality of Life Questionnaire. Results: The respondents (N = 98) were predominantly female (72.4%), with a mean age of 46 years. The respondents from South Africa reported reduced ODT access (South Africa, 72.2%; Hong Kong, 100%; and Argentina, 96.7% [ Conclusion: Disparities in ODT access and treatment behaviors persist even among countries of similar income levels. Well-controlled disease alone may be insufficient to normalize HRQoL in settings with access challenges. Locally informed strategies remain essential to reducing the burden of HAE.

Indexed as

Angioedema Control TestAngioedema Quality of LifeArgentinadisparitiesHereditary angioedemaHong Konglong-term prophylaxison-demand treatmentquality of lifeSouth Africatreatment access

Identifiers

PMID42181148

DOI10.1016/j.jacig.2026.100720

PMCPMC13196052

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.